Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10629368	
	Filing Date		2003-07-29	
	First Named Inventor Belard		ardine!li	
	Art Unit		1623	
	Examiner Name Crane		ane	
	Attorney Docket Numb	er	02-479-C	

	U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	3845770		1974-11-05	Theeuwes et al.		
	2	4326525		1982-04-27	Swanson et al.		
	3	4902514		1990-02-20	Barclay et al.		
	4	4992445		1991-02-12	Lawter et al.		
	5	5001139		1991-03-19	Lawter et al.		
	6	5032252		1991-07-16	Owen et al.		
	7	5616345		1997-04-01	Geoghegan et al.		
	8	6294522		2001-09-25	Zablocki et al.		

(Not for submission under 37 CFR 1.99)

Application Number		10629368
Filing Date		2003-07-29
First Named Inventor Belard		dinelli
Art Unit		1623
Examiner Name Crane		•
Attorney Docket Number		02-479-C

	9	6322771		2001-11-27	Linden et al.	
	10	6368573		2002-04-09	Leung	
	11	6448235		2002-09-10	Linden et al.	
	12	6552023		2003-22-04	Zablocki	
	13	6599283		2003-07-29	Marzilli et al.	
	14	6605597		2003-12-08	Zablocki et al.	
	15	6677336		2004-01-13	Zablocki	
If you wis	h to a	dd additional U.S. Pater	nt citatio	n information p	please click the Add button.	Add
			U.S.P	ATENT APPL	ICATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020111327		2002-08-25	Linden et al	
	2	20020147174		2002-10-10	Jones et al.	

(Not for submission under 37 CFR 1.99)

Application Number		10629368
Filing Date		2003-07-29
First Named Inventor Belard		dinelli
Art Unit		1623
Examiner Name	Crane	
Attorney Docket Number		02-479-C

	3	20040137533		2004-07	'-01	Hart et al.			
7 1	4	20070299089		2007-12	2-27	Belardinelli et	al.		
	5	20080170990		2008-07	'-17	Lieu et al.			
	6	20080213165		2008-09)-04	Lieu et al.			
	7	20080267861		2008-08	3-30	Lieu et al.			
lf you wis	n to a	dd additional U.S. Pub	lished Ap	•		information	please click the Add butt	on. Add	
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²	у	Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Line where Relevant Passages or Releva Figures Appear	Т5
	1	WO 99/63938	wo			1999-12-16	Epigenesis Pharm.		
	2	WO 05/082379	wo			2005-09-09	Belardinelli et al.		
If you wis	n to a	 dd additional Foreign I	atent Do	ocument	citation	information p	lease click the Add butto	on Add	
			NOI	N-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		rnal, seri	ial, symp	osium,	catalog, etc),	the article (when approp date, pages(s), volume-i		T5

(Not for submission under 37 CFR 1.99)

Application Number		10629368
Filing Date		2003-07-29
First Named Inventor Belard		dinelli
Art Unit		1623
Examiner Name Crane		
Attorney Docket Number		02-479-C

1	Cerqueira, "The Future of Pharmacologic Stress: Selective A2A Adenosine Receptor Agonists", Am. J. Cardiol. vol 94 (2A), pp. 33D-42D, July 2004	
2	Glover et al. "Characterization of a New, Highly Selective Adenosine A2A Receptor/Agonists with Potential Use in Pharmacologic Stress Perfusion Imaging", Circulation, vol. 110, pp.I-311 (1999)	
3	Hendel et al., "Pharmacologic Stress SPECT Myocardial Perfusion Imaging with a Selective A2A Agonist: Results of a Pilot Study Comparing Adenosine with CVT-3146", Circulation, Supplement IV, Vol. 108, p. IV-636 (2003)	
4	Hendel et al. "Initial Clinical Experience with Regadenoson, a Novel Selective A2A Agonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging", Journal of the American College of Cardiology, vol. 46, no. 11, pp. 2069-2075 (December 6, 2005)	
5	Kerensky et al. "Dose Dependent Increase in Human Coronary Blood Flow Velocity Following an IV Bolus of CVT-3146, A Novel A2A Adenosine Receptor Agonists: A Potential Agent for the Use in Pharmacological Stress Testing for Myocardial Perfusion Imaging", Circulation, vol. 106, p. II-618 (2002)	
6	Korolkovas, "Essentials of Molecular Pharmacology-Background for Drug Design, Wiley - Interscience, New York, NY, 1970, only pages 266-272 supplied	
7	Kusmic et al., "Coronary microcirculatory vasoconstriction induced by low-flow ischemia in mouse hearts is reversed by an A2A adenosine receptor", FASEB Journal, April 2007, A1227-A1228	
8	Koepfli et al., "Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by PET", European Heart Journal, vo. 27, no. Supp. 1, p. 175 (August 2006)	
8	Martin et al., "Pharmacology of 2-cylohexylmethylidenehydrazionoadenosine (WRC-0470), a novel, short-acting adenosine A-2A receptor agonist that produces selective coronary vasodilation", Drug Development Research, vol. 40, no. 4, pp. 313-324 (1997).	
10	Riou et al., "Influence of propranolol, enalaprilat, verapamil, and caffeine on adenosine A(2A) receptor medicated coronary vasodilation", Journal of the American College of Cardiology, vol. 40, no. 9, pp. 1687-1690 (November 6, 2002)	
11	Xu, Jiang, et al., "Coronary vasodilation by a short acting, low affinity A2A adenosine receptor agonist in anesthetize closed chest dogs: a second generation of coronary artery pharmacologic stressor", Circulation, vol. 102, no. 18 p. II 810 (2000)	

(Not for submission under 37 CFR 1.99)

Application Number		10629368
Filing Date		2003-07-29
First Named Inventor Belard		dinelli
Art Unit		1623
Examiner Name Crane		
Attorney Docket Number		02-479-C

	12	Zhao et al., "Effects of caffeine on coronary vasodilation and sinus tachycardia induced by Regadenoson, a novel adenosine A2A receptor agonist, in conscious dogs, "European Heart Journal, vol, 27, no. suppl. 1, p. 424, (August 2006)									
	13	regac	hao et al., "Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by egadenoson (CVT-3146), a novel adenosine A2A receptor agonists" Journal of Cardiovascular Pharmacology, vol. 49, o. 6, pp. 369-375 (June 2007)								
	14	Swinyard et al., "Pharmaceutical Necessities," Chapter 66 in Remington's Pharmaceutical Sciences, 18th Ed., Gennaro et al. (eds.), 1990, Mack Publishing Co, Easton, PA, only pages 1318-1319 supplied									
	15	Pending U.S. Patent Application Serial No. 12/163,099 filed June 27, 2008									
If you wis	h to a	dd add	ditional non-patent literature document citation information p	lease click the Add b	outton Add						
			EXAMINER SIGNATURE								
Examiner Signature Date Considered											
			reference considered, whether or not citation is in conformarmance and not considered. Include copy of this form with								
¹ See Kind (Codes o	of USPT	O Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office	e that issued the docume	nt, by the two-letter code (WI	IPO					

Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if

English language translation is attached.